Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/1997

01-12-1997

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

Authors: John S. Macdonald, Jacqueline K. Benedetti, Manuel Modiano, David S. Alberts

Published in: Investigational New Drugs | Issue 4/1997

Login to get access
Metadata
Title
Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)
Authors
John S. Macdonald
Jacqueline K. Benedetti
Manuel Modiano
David S. Alberts
Publication date
01-12-1997
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/1997
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1005941603420

Other articles of this Issue 4/1997

Investigational New Drugs 4/1997 Go to the issue

OriginalPaper

Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies

OriginalPaper

Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer

OriginalPaper

A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

OriginalPaper

An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92

OriginalPaper

An in vitro assessment of the antineoplastic potential of 2H-1,3-Oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine

OriginalPaper

Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits